@FierceBiotech: Industry Voices: Who will figure out how to make a business out of fecal transplants? Feature | Follow @FierceBiotech
@JohnCFierce: Bristol-Myers' "smart bomb" deal pushes Ambrx 12-month deal tally to $715M. More | Follow @JohnCFierce
@RyanMFierce: Sanofi lets go of rights to Regeneron's antibodies in ophthalmology in $65M agreement. Article | Follow @RyanMFierce
> Bayer has hit the brakes on development of a Phase II/III trial of BAY 86-6150 in some hemophilia patients over concerns about safety. Article
> Reuters' Ben Hirschler covers a spate of nanotech drug alliances with Big Pharma companies--including Pfizer ($PFE), Amgen ($AMGN), Sanofi ($SNY) and AstraZeneca ($AZN). And MIT inventor Bob Langer finds himself on the winning end of the deals. Article
> An FDA panel of outside experts unanimously voted against Delcath Systems' ($DCTH) drug-device combination product for treating cancer. Story
> The Wellcome Trust has pledged up to £5 million to fund GlaxoSmithKline's ($GSK) open research of new treatments for diseases in the developing world. Release
> Park Vale Capital will tap advice from members of the Academy of Medical Sciences to inform the company's late-stage biotech bets. Item
@FierceMedDev: Implant successfully predicts human epilepsy seizures. Item | Follow @FierceMedDev
@MarkHFierce: A Dx to predict prostate cancer recurrence produced some hopeful early results. DxExtra | Follow @MarkHFierce
@DamianFierce: Life Tech posts tepid quarterly results as Thermo waits with $13.6B. News | Follow @DamianFierce
> Medtronic lops off 230 spinal jobs, endures FDA blemish. Story
> Zimmer grabs PA startup for cutting-edge knee treatment. Article
> FDA panel rips Delcath drug/device cancer treatment. News
Pharma News
@FiercePharma: Regeneron, Eylea now 7 for 7 in beating Wall Street forecasts. More | Follow @FiercePharma
@EricPFierce: Medicare spending growth so slow that Independent Payment Board won't be in play for 2015 drug pricing pharma. Item | Follow @EricPFierce
> J&J issue in South Korea reminiscent of OTC problems here. More
> Slow Medicare spending protects pharma from payment board intravention. News
> Gilead profits surge 63%, but not where Wall Street expected. Article
> Arena pulls app for weight-loss drug Belviq in EU. Story
And Finally… GlaxoSmithKline "listened" to online chatter about vaccines for two months with data-mining tech. Article